OIFE at EMA Meeting on orphan drugs

On November 30th OIFE was represented at an interactive meeting about Orphan Drugs hosted by the European Medicines Agency (EMA).

Orphan drugs are medicinal products intended for diagnosis, prevention or treatment of rare diseases. There are currently two designated orphan drugs being investigated in OI, the most known being setrusumab from Mereo Biopharma.

Products for rare diseases are called “orphan drugs” because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients with rare conditions.

More about orphan drugs in this factsheet.

Graphic overview of Patient involvement along medicines lifecycle at EMA


Translate ยป